How to contact the center
Full member
HCP Center
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/11/Ida-Tallinna_Keskhaigla_Silmakliinik-430x160.jpg)
Internationally recognized experts of East-Tallinn Central Hospital Eye Department treat eye disorders in infants, children and adults.
Picture : Iifar
Picture : Iifar
Contact
East-Tallinn Central Hospital Eye Clinic, Tallinn, Estonia
Ravi 18
10138 Tallinn
Estonia
Team
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/11/klett-230x230.png)
Dr Artur Klett
Representative
Estonia
Anterior Segment Rare Eye Diseases (WG4), National Integration (TWG9)
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/11/i-bKhP4DW-X4-180x230.jpg)
Dr Kristel Harak
Estonia
Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Registries & Epidemiology (TWG7), Retinal Rare Eye Diseases (WG1)
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/11/Eerme-Katrin-2-180x230.jpg)
Dr Katrin Eerme
Estonia
Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/11/Rebane-230x230.jpg)
Dr Reili Rebane
Estonia
CPMS & Digital Medecine (TWG10), Pediatric Ophthalmology Rare Diseases (WG3)
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/09/john-doe.jpg)
Dr Delis Linntam
Estonia
Anterior Segment Rare Eye Diseases (WG4), Retinal Rare Eye Diseases (WG1)
Clinical trials
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/09/john-doe.jpg)
NCT04423718 - Active, Not recruiting
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Interventional
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/09/john-doe.jpg)
NCT04270747 - Completed
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration
Interventional
![](https://www.ern-eye.eu/wp-content/uploads/sites/2/2023/09/john-doe.jpg)
NCT02686658 - Completed
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Interventional